DelveInsight’s, “Vascular Dementia Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Vascular Dementia pipeline landscape.

 

Vascular Dementia Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Vascular Dementia Pipeline Report

• DelveInsight’s Vascular Dementia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Vascular Dementia treatment.
• Leading Vascular Dementia Companies such as Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others are evaluating Vascular Dementia drugs candidate to improve the treatment landscape.
• Vascular Dementia pipeline therapies in various stages of development includes BAC (also called CSTC1, CHARSIRE Trauma Complex 1), PNA1, Apabetalone, CY6463, AR1001, PNA5, and others.
• Akatinol Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine is marketed for the treatment of moderate to severe Alzheimer’s disease. Memantine works by blocking NMDA receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another and overstimulation of the NMDA receptors can result in cell damage or death. The drug is in Phase III clinical development for the treatment of Vascular Dementia.
• Butylphthalide (NBP) is a compound found in Chinese celery seed extracts that can improve cognitive functions and may decrease Amyloid-beta levels in Alzheimer′s disease. NBP has antioxidant activities and may protect against oxidative/nitrosative stress, mitochondrial impairment and apoptosis. The drug is currently in Phase III stage of development for the treatment of patients with Vascular Dementia.
• Sailuotong (SLT) capsule is a standardized three-herb preparation composed of ginseng, ginkgo, and saffron being evaluated for the treatment of vascular dementia in Phase III stage of development.

 

Request a Sample Copy and discover the recent advances in vascular dementia pipeline report @ Vascular Dementia Pipeline Outlook

 

Vascular Dementia Overview

Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. Cognitive changes in vascular dementia are much more variable than in other disorders such as Alzheimer’s disease, and are highly dependent on the particular neural substrates affected by the vascular pathology. Some symptoms may be similar to those of other types of dementia. Memory loss is common in the early stages of Alzheimer’s, but is not usually the main early symptom of vascular dementia.

Vascular Dementia is caused by reduced blood supply to the brain due to diseased blood vessels. To be healthy and function properly, brain cells need a constant supply of blood to bring oxygen and nutrients. Blood is delivered to the brain through a network of vessels called the vascular system. If the vascular system within the brain becomes damaged – so that the blood vessels leak or become blocked – then blood cannot reach the brain cells and they will eventually die. There is currently no cure for vascular dementia: the brain damage that causes it cannot be reversed. However, there is a lot that can be done to enable someone to live well with the condition. This will involve drug and non-drug treatment, support and activities.

 

Vascular Dementia Pipeline Insights

Vascular Dementia Pipeline Insight 2022 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Vascular Dementia Emerging Drugs

• Akatinol Memantine: Merz Pharma 
• Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical 
• SaiLuoTong: Shineway Pharmaceutical

 

Learn more about the novel and emerging Vascular Dementia pipeline therapies @ Vascular Dementia Clinical Trials

 

Vascular Dementia Pipeline Therapeutics Analysis

There are approx. 12+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. phase III include, Merz Pharma.

 

Vascular Dementia Pipeline Report

• The report provides detailed insights about emerging therapies for Vascular Dementia treatment and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vascular Dementia Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Vascular Dementia Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vascular Dementia market.

The Vascular Dementia Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.

 

Scope of the Vascular Dementia Pipeline Report

• Coverage- Global
• Vascular Dementia Companies- Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others.
• Vascular Dementia Therapies- includes BAC (also called CSTC1, CHARSIRE Trauma Complex 1), PNA1, Apabetalone, CY6463, AR1001, PNA5, and others
• Vascular Dementia Therapeutic Assessment by Product Type
• Vascular Dementia Therapeutic Assessment by Stage and Product Type
• Vascular Dementia Therapeutic Assessment by Route of Administration
• Vascular Dementia Therapeutic Assessment by Stage and Route of Administration
• Vascular Dementia Therapeutic Assessment by Molecule Type
• Vascular Dementia Therapeutic Assessment by Stage and Molecule Type
• Vascular Dementia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
• Vascular Dementia- Market Drivers and Barriers
• Vascular Dementia- Future Perspectives and Conclusion

 

Table of Content

1. Introduction
2. Executive Summary
3. Vascular Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vascular Dementia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Vascular Dementia Collaboration Deals
9. Late Stage Products (Phase III)
10. Akatinol Memantine: Merz Pharma
11. Mid Stage Products (Phase II)
12. CY6463: Cyclerion therapeutics
13. Early stage products (Phase I)
14. AR1001: AriBio
15. Inactive Products
16. Vascular Dementia Key Companies
17. Vascular Dementia Key Products
18. Vascular Dementia- Unmet Needs
19. Vascular Dementia- Market Drivers and Barriers
20. Vascular Dementia- Future Perspectives and Conclusion
21. Vascular Dementia Analyst Views
22. Vascular Dementia Key Companies
23. Appendix

 

For further information on the Vascular Dementia Pipeline therapeutics, reach out to Vascular Dementia Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/